

Catalog Number: 24349-1, 24349-2

Amount: 50µg/50µl, 100µg/100µl

Swiss-Prot No. :P30086

Form of Antibody: Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl,0.02% sodium azide and 50% glycerol.

Storage/Stability: Store at -20°C/1 year

Immunogen: The antiserum was produced against synthesized peptide derived from Human PEBP1 **Purification:**The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Specificity/Sensitivity:PEBP1 Antibody detects endogenous levels of total PEBP1

Reactivity: Human, Mouse, Rat

Applications:

150-100-

> 75-50-37-

20-

Predicted MW:21kd WB:1:500-2000 IHC:1:50-200

Western blot analysis of testis cell and briancelllysate

using PEBP1 antibody.

Background :Raf kinase inhibitor protein (RKIP) is a member of the phosphatidylethanolamine-binding protein (PEBP) family that associates with Raf-1 and the MEK and MAP kinases . RKIP has been shown to complex with Raf-1, MEK, and ERK . Although MEK and ERK can simultaneously bind RKIP, the association between Raf-1 and RKIP and that of RKIP and MEK are mutually exclusive. Thus, RKIP competitively disrupts the Raf-1-MEK complex and effectively terminates signal transmission from Raf-1 to MAP kinases . The inhibitory effect of RKIP on MAP kinase signaling is eliminated by PKC phosphorylation of RKIP at Ser153 . PKC phosphorylation on Ser153 also promotes the association of RKIP with GRK2, which prevents GRK2-dependent internalization of GPCR . RKIP also interacts with modules of the NF- κ B pathway, including NF- κ B-inducing kinase (NIK), TAK1, IKK α and IKK β . These interactions antagonize cytokine-induced activation of the NF- κ B pathway . Restoration of RKIP expression is associated with the inhibition of prostate cancer metastasis, implying that RKIP may be a potential clinical target as a suppressor of tumor metastasis through inhibition of vascular invasion .